CXCR6 and metabolic dysfunction-associated steatohepatitis: In contrast, when given prophylactically in a mice model of NASH, anti-PD1 treatment led to an increase in the incidence of NASH induced HCC and in the number and size of tumor nodules, which correlated with increased hepatic PD1+ CXCR6+ CD8+ T cells and TNF+ T cells (73).